Some biosimilar product sponsors are doing more clinical studies than FDA believes necessary to support licensure.
"We are seeing biosimilar sponsors proposing to do multiple studies in multiple indications, which to us is not the right...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?